Changes in Executive Management at Sosei
19 Gennaio 2018 - 02:54AM
Business Wire
- Dr. Fiona Marshall, Executive Vice
President and Chief Scientific Officer of Sosei to leave to assume
new role outside the company
- Sosei R&D to continue under the
leadership of Dr. Malcolm Weir, Executive Vice President and Chief
R&D Officer
- Dr. Tim Tasker appointed Executive Vice
President and Chief Medical Officer of Sosei
Sosei Group Corporation (“Sosei” or the “Company”) (TOKYO:
4565), the world leader in GPCR medicine design and development,
today announced that Dr. Fiona Marshall has resigned from her
position as Executive Vice President and Chief Scientific Officer
of Sosei to assume a senior role outside the Company. Dr. Marshall
will leave Sosei at the end of February 2018.
“As a co-founder of Heptares, I am very proud to have been
associated with building a team of talented scientists over the
past decade that has made many important breakthroughs in the field
of GPCR stabilization and structure-based drug design, a unique
technology that now underpins Sosei’s powerful drug discovery
capability,” said Dr. Marshall. “With the team in excellent hands,
I feel the time is right for me to move on to new challenges and I
wish everyone at Sosei the best for what looks set to be an
exciting future for the Company.”
Peter Bains, Chief Executive Officer of Sosei, added: “Fiona has
been a pivotal figure in advancing the science of GPCR
stabilization, and in creating Sosei StaR® technology, a legacy
that in time we believe will lead to the development of new and
innovative medicines. Thanks to Fiona, we have built a deep pool of
talented scientists who will continue to carry on our world-leading
work in GPCR-focused drug discovery and development and execute on
our vision to become a fully integrated global biotechnology
company. The Board and I express our sincere thanks to Fiona for
her significant contributions to Sosei and wish her the very best
in her exciting new role.”
Sosei’s R&D activities will continue under the leadership of
Dr. Malcolm Weir, co-founder and Chief Executive Officer of
Heptares, and Executive Vice President and Chief R&D Officer of
Sosei.
Separately, and reflecting the progress of Sosei’s proprietary
pipeline of drug development candidates, Dr. Tim Tasker is promoted
to the Executive management team of Sosei as an Executive Vice
President and Chief Medical Officer (CMO). Dr. Tasker will continue
to report to Dr. Malcolm Weir, Chief R&D Officer.
Peter Bains commented: “Tim’s promotion is thoroughly deserved
and reflects the increasing importance of clinical development
expertise in the team. This expertise is crucial to supporting our
partnered programs and more importantly to drive our proprietary
programs, of which we plan to advance at least six candidates into
clinical studies over the next two years, including HTL0018318, our
selective muscarinic M1 agonist, which we expect to start a Phase
II trial in patients with dementia with Lewy bodies (DLB) in Japan
during this year.”
About Sosei
Sosei is an international biopharmaceutical company focused on
the design and development of new medicines originating from its
proprietary GPCR-targeted StaR® technology and structure-based drug
design platform capabilities. The Company is advancing a broad and
deep pipeline of partnered and wholly owned product candidates in
multiple therapeutic areas, including CNS, cancer, metabolic
diseases and other rare/specialty indications. The Company’s
leading clinical programs include a proprietary Phase II candidate
for dementia with Lewy bodies (DLB) in Japan, together with
partnered candidates aimed at the symptomatic treatment of
Alzheimer’s disease (with Allergan) and immuno-oncology approaches
to treat cancer (with AstraZeneca). Sosei’s additional partners and
collaborators include Novartis, Teva, Pfizer, Daiichi-Sankyo,
PeptiDream, Kymab and MorphoSys. The Company is headquartered in
Japan with R&D facilities in the UK.
Sosei is listed on the Mothers Index of the Tokyo Stock Exchange
(TOKYO: 4565). For more information, please visit
http://www.sosei.com/en/.
Sosei Forward-looking statements
This press release may contain forward-looking statements,
including statements about the discovery, development and
commercialisation of products. Various risks may cause Sosei’s
actual results to differ materially from those expressed or implied
by the forward-looking statements, including: adverse results in
clinical development programmes; failure to obtain patent
protection for inventions; commercial limitations imposed by
patents owned or controlled by third parties; dependence upon
strategic alliance partners to develop and commercialise products
and services; difficulties or delays in obtaining regulatory
approvals to market products and services resulting from
development efforts; the requirement for substantial funding to
conduct research and development and to expand commercialisation
activities; and product initiatives by competitors. As a result of
these factors, prospective investors are cautioned not to rely on
any forward-looking statements. We disclaim any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180118006528/en/
Sosei Group CorporationChris Cargill, +44 (0)7912 892 199Head of
Investor Relations and Corporate
Communicationsccargill@sosei.comorCitigate Dewe Rogerson (for
International media)Mark Swallow / David Dible, +44 (0)20 7638
9571sosei@citigatedewerogerson.com